— Know what they know.
Not Investment Advice

UPB NASDAQ

Upstream Bio, Inc.
1W: -6.0% 1M: -22.2% 3M: -31.9% YTD: -80.7% 1Y: -70.9%
$5.04
+0.00 (+0.00%)
 
Weekly Expected Move ±6.0%
$4 $5 $5 $5 $6
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 30 · $274.3M mcap · 20M float · 3.04% daily turnover · Short 33% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$274.3M
52W Range4.87-33.68
Volume956,519
Avg Volume610,300
Beta1.29
Dividend—
Analyst Ratings
3 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOE. Rand Sutherland
Employees75
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
890 Winter Street
Waltham, MA 02451
US
781 208 2466
About Upstream Bio, Inc.

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
GRAY MICHAEL S-Sale 853 $5.49 2026-09-16
Ambrose Allison S-Sale 485 $5.49 2026-09-16
Deykin Aaron S-Sale 895 $5.49 2026-09-16
Sutherland Everett R S-Sale 2,095 $5.49 2026-09-16
Houghton Adam S-Sale 700 $5.49 2026-09-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms